The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.
Antimicrob Agents Chemother
; 2021 Mar 01.
Article
in English
| MEDLINE | ID: covidwho-2284291
ABSTRACT
Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.
.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Prognostic study
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
AAC.00020-21
Similar
MEDLINE
...
LILACS
LIS